BioSpace News Archive

Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, announces the acquisition of Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics.

AbbVie will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022.

Qualigen Therapeutics, Inc., a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces that its board of directors has approved a 1-for-10 reverse stock split of the Company’s common stock.

DexCom, Inc. announced that Matt Dolan, Executive Vice President, Strategy, Corporate Development and Dexcom Labs, will present an update on the company at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022 at 8:30am.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual HealthCONx Conference.

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in H.C. Wainwright & Co.’s 2022 KOL Series (Part 8) on Tuesday, November 29, at 11 a.m. EST.

Standard BioTools Inc. announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of November 20, 2022, under the Standard BioTools Inc.

Novartis will present data on the latest advancements in breast cancer and hematology at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, and the American Society of Hematology (ASH) Annual Meeting, December 10-13.

JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds the decision from the U.S Food and Drug Administration (FDA) to approve Provention Bio’s teplizumab.

uLab Systems™, creator of the uSmile™ clear aligner system and uDesign® treatment planning software, announces the establishment of a separate business line to manufacture private-label aligner products.